Publications

5600 Results

Results of Alliance A031201: A Phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for men with metastatic castration resistant prostate cancer (mCRPC)

Authors
MJ Morris;G Heller;A Bryce;A Armstrong;H Beltram;O Hahn;E McGary;P Mehan;A Goldkorn;B Roth;H Xiao;ME Taplin;CJ Ryan;S Halabi;E Small
Journal / Conference
J Clin Oncol 37(suppl; abstr 5008); American Society of Clinical Oncology (5/31/2-6/4/19, Chicago IL), oral
Year
2019
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/A031201

Alliance A091404: A Phase II Study of ENZALUTAMIDE (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers

Authors
AL Ho;NR Foster;AJ Zoroufry;FP Worden;K Price;D Adkins;D Bowles;H Kang;B Burtness;E Sherman;R Morton;N Katabi;P Munster
Journal / Conference
J Clin Oncol 37(suppl; abstr 6020); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), poster discussion
Year
2019

CALGB/Alliance 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) (+/- carboplatin (Cb) and bevacizumab (Bev)) in triple-negative breast cancer (TNBC)

Authors
W Sikov;M-Y Polley;E Twohy;C Perou;B Singh;DA Berry;S Tolaney;G Somlo;E Port;R Qamar;K Sturtz;E Mamounas;M Golshan;J Bellon;D Collyar;O Hahn;C Hudis;E Winer;A Partridge;L Carey
Journal / Conference
J Clin Oncol 37(suppl; abstr 591); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), poster session
Year
2019
Research Committee(s)
Breast
Study Number(s)
CTSU/C40603

CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC)

Authors
JA Eastham;G Heller;S Halabi;P Monk;SK Clinton;R Zelig Szmulewitz;J Coleman;M Gleave;CP Evans;CW Hillman;H Beltran;ME Taplin;OM Hahn;JK Parsons;EJ Small;J Mohler;MJ Morris
Journal / Conference
J Clin Oncol 37(suppl; abstr 5079; American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), poster session
Year
2019
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/C90203

Associations of Insulin-Like Growth Factor Binding Proteins and Adiponectin with Disease Progression and Mortality in Metastatic Colorectal Cancer: Results from CALGB/SWOG 80405 (Alliance)

Authors
B Guercio;A Venook;S Zhang;F-S Ou;D Niedzwiecki;H-J Lenz;F Innocenti;M Pollak;AB Nixon;M Mahoney;B O'Neil;J Shaw;B Polite;CS Denlinger;J Atkins;R Goldberg;R Mayer;CD Blanke;CS Fuchs;J Meyerhardt
Journal / Conference
J Clin Oncol 37(suppl; abstr 3035); American Society of Clinical Oncology (5/31- 6/4/2019, Chicago IL), poster session
Year
2019
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

CALGB 90601 (Alliance): Randomized, double blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma

Authors
J Rosenberg;K Ballman;S Halabi;C Watt;R Dreicer;T Flaig;M Morris
Journal / Conference
J Clin Oncol 37(suppl; abstr 4503); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), oral
Year
2019
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/C90601

United States Intergroup E1609 - A Phase III Randomized Study of Adjuvant Ipilimumab (3 or 10 mg/kg) versus High-Dose Interferon-a2b for Resected High-Risk Melanoma

Authors
A Tarhini;S Lee;F Hodi;U Rao;GI Cohen;O Hamid;L Hutchins;J Sosman;H Kluger;V Sondak;H Koon;DP Lawrence;K Kendra;DR Minor;C Lee;M Albertini;L Flaherty;T Petrella;JM Kirkwood
Journal / Conference
J Clin Oncol 37(suppl; abstr 9504); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), oral
Year
2019
Research Committee(s)
Melanoma
Study Number(s)
CTSU/E1609

Randomized, DoubleBlind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastasectomy: A Trial of the ECOG-ACRIN Cancer Research Group (E2810)

Authors
LJ Appleman;M Puligandla;SK Pal;W Harris;N Agarwal;B Addis Costello;CW Ryan;M Pins;JE Kolesar;DA Vaena;RA Parikh;M Hashmi;JP Dutcher;RS DiPaola;N Haas;M Carducci
Journal / Conference
J Clin Oncol 37(suppl; abstr 4502); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), oral
Year
2019
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/E2810

HSD3B1 and Overall Survival (OS) in Men with Low-Volume (LV) Metastatic Prostate Cancer (PCa) Treated with Androgen Deprivation Therapy (ADT) or Chemohormonal Therapy in the CHAARTED Randomized Trial

Authors
J Hearn;C Sweeney;N Almassi;C Reichard;C Reddy;B Hobbs;DF Jarrard;Y-H Chen;R Dreicer;JA Garcia;M Carducci;R DiPaola;N Sharifi
Journal / Conference
J Clin Oncol 37(suppl; abstr 5020); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), poster discussion
Year
2019
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/E3805

Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx

Authors
J Sparano;RJ Gray;D Makower;T Lively;T Saphner;M Keane;HL Gomez;PS Reddy;T Goggins;I Mayer;D Toppmeyer;A Brufsky;M Goetz;D Hayes;C Dees;K Pritchard;CE Geyer;JA Olson;K Albain;G Sledge
Journal / Conference
J Clin Oncol 37(suppl; abstr 503); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), oral
Year
2019
Research Committee(s)
Breast